|Articles|October 11, 2022
- Pharmaceutical Executive-10-01-2022
- Volume 42
- Issue 10
Pharmaceutical Executive, October 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 3 years ago
Healthy Planet, Healthy People: How Pharma Can Lead the Wayabout 3 years ago
At the Heart of Pharma: ESG has Arrived as a Central Strategyabout 3 years ago
Keeping it Simpleabout 3 years ago
All About the Rates: The Fallout of Fed Hikes for Biotechabout 3 years ago
Exploring Fixed and Variable Coverage Principlesabout 3 years ago
Inclusion Check-In: Who are You Giving Your Energy To?about 3 years ago
Cracking the Code to Commercial Promise in Asiaabout 3 years ago
Push for Full Embrace of Digital Care Draws Opposition in Europeabout 3 years ago
Seeking Harmonized Testing, Regulation, and ManufacturingNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
